Cargando…
The dihydropyridine calcium channel blocker benidipine prevents lysophosphatidylcholine-induced endothelial dysfunction in rat aorta
BACKGROUND: Lysophosphatidylcholine (LPC), an atherogenic component of oxidized low-density lipoprotein, has been shown to induce the attenuation of endothelium-dependent vascular relaxation. Although benidipine, a dihydropyridine-calcium channel blocker, is known to have endothelial protective effe...
Autores principales: | Takayama, Makoto, Yao, Kozo, Wada, Michihito |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710319/ https://www.ncbi.nlm.nih.gov/pubmed/19558657 http://dx.doi.org/10.1186/1423-0127-16-57 |
Ejemplares similares
-
Dihydropyridine Calcium Channel Blockers and the Risk of Severe COVID-19
por: Mendez, Sean R., et al.
Publicado: (2021) -
Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial
por: Umemoto, Seiji, et al.
Publicado: (2017) -
Dihydropyridine-derived calcium channel blocker as a promising anti-hantavirus entry inhibitor
por: Wang, Bin, et al.
Publicado: (2022) -
A(2B) adenosine receptor inhibition by the dihydropyridine calcium channel blocker nifedipine involves colonic fluid secretion
por: Asano, Teita, et al.
Publicado: (2020) -
Dihydropyridine Calcium Channel Blockers and Risk of Pancreatic Cancer: A Population‐Based Cohort Study
por: Rouette, Julie, et al.
Publicado: (2022)